Sandoz CEO Steps Down as Novartis Transforms Its Generics Unit

诺华旗下仿制药单元山德士正值转型期,首席执行官辞职

2019-03-15 17:42:00 BioSpace

本文共1244个字,阅读需4分钟

标签: 医药/器械 医药 生物制药/生物制品 仿制药
Richard Francis, chief executive officer of Sandoz, has stepped down from his position as parent company Novartis undertakes a year-and-a-half-long transformation of its Sandoz business unit. Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis Francis has helmed the generics subsidiary for five years. In a statement, Francis said the past five years have been both satisfying and rewarding. In his statement, Francis pointed to the transformation that Sandoz is expected to undertake. He said it’s a multi-year project that is something he cannot commit to. “… and therefore (I) have decided that now is the right time to step down,” Francis said. “I am very proud of what we have achieved as a team. Together, we have expanded access to medicines across the world and reached many millions of patients. In particular, we have successfully launched five biosimilar products.” Narasimhan touted the successes Sandoz has seen under the guidance of Francis. He noted that during his tenure at Sandoz, the company has become a leader in biosimilar development. Narasimhan also noted that Francis has helped guide Sandoz through “changing market dynamics and challenging headwinds in the U.S.” “Now, as we initiate a multi-year transformation program for the business and move to make it more autonomous, Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed. I understand his decision and wish him the very best for the future,” Narasimhan said. Balestrieri, who will take over for Francis, has spent the last eight years running commercial operations in generics. His most recent role was as head of Sandoz Europe, which represents half of the Sandoz' global sales and organization. He has been with Novartis for 25 years. Since taking over as head of Novartis, Narasimhan has initiated a number of changes for Sandoz. In September, the company sold U.S. dermatology and generic drug assets that were under the Sandoz umbrella to India’s Aurobindo Pharma. Dermatology products that were part of the deal included topical antibiotics, gynecological and dermatological antifungal medications, anti-acne drugs, local anesthetics and painkillers, anti-itch medications, and a dermatological chemotherapy drug. The oral non-dermatological assets that were part of the deal included products that ranged from auto-immune diseases, anti-neoplastic drugs and hormonal therapies. While Novartis has said it is transforming Sandoz, there has been some speculation the company plans to spin it off or divest it completely. Zuercher Kantonalbank analyst Michael Nawrath told Reuters that spinning out Sandoz would actually align with Novartis’ current strategy that has included significant house cleaning of some assets. “Even though the Novartis chairman said recently Sandoz isn’t for sale for now, a spin-off like they’re doing with Alcon would align with the strategy of becoming a focused, pure-play drugmaker,” Nawrath told Reuters.
Sandoz 首席执行官理查德•弗朗西斯( Richard Francis )辞去了母公司诺华( Novartis )的职务,对其 Sandoz 业务部门进行了为期一年半的转型。 Francis 与 Sandoz 的最后一天将是3月31日。弗朗西斯科•巴尔埃斯特里( FrancescoBalesterii )目前是 Sandoz 欧洲地区负责人,他被任命为临时首席执行官。他将向诺华(Novartis)首席执行官 Vas Narasimhan 报告 弗朗西斯执掌这家仿制药子公司已经五年了。弗朗西斯在一份声明中说,过去五年来,这既是令人满意的,也是有益的。在他的发言中, Francis 指出了 Sandoz 将进行的转变。他说,这是一个多年的项目,是他无法承诺的。 弗朗西斯说:“因此(我)决定现在是下台的合适时机。”“我对我们作为一个团队所取得的成就感到非常自豪。我们一起扩大了世界各地的药品供应,接触了数百万病人。特别是,我们成功地推出了五种生物生物仿制药产品。” 纳拉希姆汉吹捧桑多斯在弗朗西斯的指导下取得的成功。他指出,在他任职于 Sandoz 期间,该公司已成为生物仿制药发展的领导者。Narasimhan 还指出, Francis 帮助引导 Sandoz 走出“不断变化的市场动态和挑战美国的逆风”。 “现在,当我们启动一项多年的业务转型计划,并采取行动使之更具自主性时,理查德决定,出于个人原因,在转型完成之前,他不能承诺留在 Sandoz 。我理解他的决定,并希望他为未来做最好的事情。” Balestrieri 将接管 Francis ,在过去的八年里,他一直在经营仿制药的商业业务。他最近担任 SandozEurope 的负责人,代表 Sandoz 全球销售和组织的一半。他在诺华(Novartis)公司工作了25年。 自接任诺华(Novartis)公司总裁以来, Narasimhan 为 Sandoz 发起了一系列变革。今年9月,该公司将 Sandoz 保护伞下的美国皮肤科和仿制药资产出售给印度的 Aurobindo Pharma 。本次交易涉及的皮肤类产品包括外用抗生素、妇科和皮肤科抗真菌药物、抗痤疮药物、局部麻醉剂和止痛药、止痒药物、皮肤科化疗药物等。本次交易中涉及的口腔非皮肤类资产包括自免疫疾病、抗肿瘤药物和激素治疗等产品。 尽管诺华(Novartis)表示正在转型 Sandoz ,但有人猜测该公司计划剥离或彻底剥离 Sandoz 。Zuerher Kantonalbank 分析师 MichaelNawrth 对路透表示,剥离 Sandoz 实际上符合诺华(Novartis)当前的战略,包括对部分资产进行重大的房屋清理. “尽管诺华(Novartis)董事长最近表示, Sandoz 暂时不会出售,但与美国铝业( Alcon )类似的分拆,将与成为一家专注、纯粹的制药企业的战略相一致,” Nawrath 对路透社( Reuters )表示。